LitCovid-sentences  

PMC:7242013 / 11193-13521 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T129 0-82 Sentence denotes What Are the Roles of a Hepatologist in the Management of a Patient With COVID‐19?
T130 83-218 Sentence denotes Elevation of serum transaminase levels is commonly observed in patients with COVID‐19, and a hepatologist might therefore be consulted.
T131 219-395 Sentence denotes All of the guidance suggests that the underlying cause of liver injury may be related to SARS‐CoV‐2 infections, exacerbation of preexisting CLD, or drug‐induced hepatotoxicity.
T132 396-466 Sentence denotes AASLD and APASL provide an algorithm to clinical evaluations (Fig. 1).
T133 467-550 Sentence denotes A key question is whether patients with CLD have a higher risk for severe COVID‐19.
T134 551-736 Sentence denotes AASLD and APASL suggest nonalcoholic fatty liver disease (NAFLD) as an independent prognostic factor, and patients with CLD should be prioritized as candidates for COVID‐19 drug trials.
T135 737-865 Sentence denotes EASL and AASLD mention that patients with NAFLD are more likely than others to have other comorbidity risks for severe COVID‐19.
T136 866-1042 Sentence denotes To date, there is no evidence that patients with stable CLD due to chronic hepatitis B (CHB) or chronic hepatitis C (CHC) have increased susceptibility to SARS‐CoV‐2 infection.
T137 1043-1192 Sentence denotes It is controversial whether there is an increased risk for flare‐up of CHB or CHC during COVID‐19 and whether prophylactic therapy should be started.
T138 1193-1286 Sentence denotes Both AASLD and APASL recommend continuing treatment for CHB or CHC in patients with COVID‐19.
T139 1287-1404 Sentence denotes APASL recommends prophylactic hepatitis B therapy for those planned for anti‐IL‐6 or other immunosuppressive therapy.
T140 1405-1468 Sentence denotes Initiating prophylactic hepatitis C therapy is not recommended.
T141 1469-1618 Sentence denotes If there is any suggestion of a flare‐up, therapy should be initiated in patients who are not already receiving hepatitis B or hepatitis C treatment.
T142 1619-1704 Sentence denotes Fig 1 Approach to the patient with COVID‐19 and elevated serum liver biochemistries.
T143 1705-1748 Sentence denotes Reproduced with permission from Hepatology.
T144 1749-1821 Sentence denotes 5 Copyright 2020, American Association for the Study of Liver Diseases.
T145 1822-2043 Sentence denotes On May 1, 2020, remdesivir, a nucleotide RNA polymerase inhibitor, was authorized by the US Food and Drug Administration under Emergency Use Authorization for treatment of those patients hospitalized with severe COVID‐19.
T146 2044-2180 Sentence denotes 9 APASL and AASLD recommend close monitoring of liver function in patients, especially those with CLD, who are treated with remdesivir.
T147 2181-2328 Sentence denotes Patients with decompensated CLD and those with alanine aminotransferase (ALT) >5 times upper limit of normal should not be treated with remdesivir.